Johnson & Johnson's (JNJ) shares were edging lower Tuesday after S&P Global Ratings said it placed nearly all of the company's ratings on creditwatch with negative implications following the drugmaker's $14.6 billion deal to acquire Intra-Cellular Therapies (ITCI).
The ratings agency said that the negative creditwatch reflects concerns that while the company has reduced its debt after each acquisition, its leverage may occasionally exceed 1.0 times, which the ratings agency views as inconsistent with the current 'AAA' rating.
S&P said it plans to resolve the creditwatch status after reviewing the company's full-year 2024 results, 2025 guidance, as well as more details about the transaction, and additional information on management's financial policies regarding future mergers and acquisitions. It also said it will assess the impact of the ongoing talcum powder litigation settlement on the company's adjusted leverage.
Price: 143.64, Change: -0.83, Percent Change: -0.57
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。